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ABSTRACT
Patients with hormone-resistant prostate cancer (PCa) have higher biochemical
failure rates following radiation therapy (RT). Cyclin D1 deregulated expression in PCa
is associated with a more aggressive disease: however its role in radioresistance has
not been determined. Cyclin D1 levels in the androgen-independent PC3 and 22Rv1
PCa cells were stably inhibited by infecting with cyclin D1-shRNA. Tumorigenicity
and radiosensitivity were investigated using in vitro and in vivo experimental assays.
Cyclin D1 silencing interfered with PCa oncogenic phenotype by inducing growth
arrest in the G1 phase of cell cycle and reducing soft agar colony formation, migration,
invasion in vitro and tumor formation and neo-angiogenesis in vivo. Depletion of cyclin
D1 significantly radiosensitizes PCa cells by increasing the RT-induced DNA damages
by affecting the NHEJ and HR pathways responsible of the DNA double-strand break
repair. Following treatment of cells with RT the abundance of a biomarker of DNA
damage, γ-H2AX, was dramatically increased in sh-cyclin D1 treated cells compared to
shRNA control. Concordant with these observations DNA-PKcs-activation and RAD51accumulation, part of the DNA double-strand break repair machinery, were reduced
in shRNA-cyclin D1 treated cells compared to shRNA control. We further demonstrate
the physical interaction between CCND1 with activated-ATM, -DNA-PKcs and RAD51 is
enhanced by RT. Finally, siRNA-mediated silencing experiments indicated DNA-PKcs
and RAD51 are downstream targets of CCND1-mediated PCa cells radioresistance.
In summary, these observations suggest that CCND1 is a key mediator of PCa
radioresistance and could represent a potential target for radioresistant hormoneresistant PCa.

INTRODUCTION

be used alone, as adjuvant to surgery and/or combined
with androgen deprivation therapy [1]. Although, RT
generally results in an excellent initial response, some
patients relapse locally and/or systemically, indicating
that a resistant population of cancer cells may have
survived the RT [1–2]. Clinical observation shows that
patients with androgen-independent PCa appear to

Prostate cancer (PCa) is the most commonly
diagnosed male malignancy and the second leading
cause of cancer death in men. Radiation therapy (RT),
considered as a major therapeutic modality for PCa
treatment, is a non-invasive outpatient therapy that can
www.impactjournals.com/oncotarget
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have higher biochemical failure rates after RT. Previous
studies also indicate that the response to RT is different
between androgen-dependent and androgen-independent
PCa cells, indicating that molecular events mediated by
androgen may also function in radiosensitization and that
androgen-independency may be associated with radiation
resistance in PCa [3]. Although various genetic, epigenetic
and molecular abnormalities have been associated with
radiation resistance in PCa [4], the molecular mechanisms
responsible of radiation resistance and relationship
with androgen-independent PCa phenotype remains
unknown. Understanding these phenomena could lead to
new molecular targets and more directed therapy able to
improve the RT efficiency.
RT promotes cytotoxicity by inducing several forms
of DNA damage such as double-strand breaks (DSBs).
Two mechanisms exist to repair mammalian DSBs:
non-homologous end joining (NHEJ) and homologous
recombination (HR) that are chosen depending in part
upon the phase of the cell cycle and chromatin context
[5]. It is generally considered that accurate repair by
HR is restricted to S and G2 phases of the cell cycle,
whereas NHEJ is predominant in G0/G1 cells [5–6].
Ataxia telangiectasia mutated (ATM) and the DNA
dependent protein kinase catalytic subunit (DNA-PKcs)
play a key roles in the DSBs response, via HR and NHEJ,
respectively. Once activated, ATM and DNA-PKcs regulate
a wide spectrum of downstream targets that are involved
in the DNA damage repair process, cell cycle regulation
and apoptosis [7]. Tumor cells escape from RT induced
cytotoxicity by activating a complex network of pathways
able to remove DSBs and to permit cell cycle progression
[5]. Furthermore, RT can also simultaneously induce
multiple pro-survival signaling pathways which can lead
to suppression of apoptosis, induction of cell cycle arrest
and/or initiation of DNA repair. These signaling pathways
act in concert to reduce the magnitude of radiationinduced cytotoxicity and promote the development of
radioresistance in cancer cells [8–9]. The identification of
the molecular mechanisms involved in the DNA damage
response raises the possibility to specifically target cancer
cells inducing a radiosensitization [10–11].
The D-type cyclin family, composed of three
proteins, Cyclin D1, D2 and D3, regulates the G1/Sphase transition of proliferating cells [12]. Of the three
D-type cyclins, it is cyclin D1 overexpression that is
predominantly associated with human tumorigenesis
and cellular metastases. Amplification or overexpression
of cyclin D1 plays pivotal roles in the development of a
subset of human cancers including parathyroid adenoma,
breast cancer, colon cancer, lymphoma, melanoma, and
prostate cancer [13–16]. Increasing evidences show
that cyclin D1 governs DNA damage repair through
forming and regulating several multi-protein DNA
repair complexes that participate in DNA repair [17–22].
Despite the evidence collected implicating cyclin D1
www.impactjournals.com/oncotarget

in DNA repair and radioresistance of cancer cells, little
is known about its role in prostate cancer cells and the
relationship between cyclin D1, androgen independency
and radioresistance.
In this manuscript, we investigated whether
silencing cyclin D1 affects the radiosensitivity of
androgen-independent, androgen-receptor negative PC3
[23–24] and androgen-independent, androgen-receptor
positive 22Rv1 cells [25] by deploying in vitro and
in vivo models systems. We generated stably infected cell
lines expressing shRNA against cyclin D1. Herein, cyclin
D1 depletion suppressed the tumorigenic phenotype and
increased the radiosensitivity of PCa cell lines both in vitro
and in vivo. Cyclin D1 silencing impaired the DSBs repair
mediated by the NHEJ and HR molecular machinery.
These results substantiate the idea that cyclin D1 is an
important regulator of tumorigenesis and radioresistance
of androgen-independent PCa cells.

RESULTS
Silencing cyclin D1 affects the cell lines PC3 and
22Rv1 oncophenotype
An shRNA sequence versus cyclin D1, cloned in the
GFP-expressing pLVTHM plasmid, was used to knock
down expression of cyclin D1 in the PC3 (Figure 1) and
22Rv1 (Figure 2) PCa cell lines. As extensively described
in the Material and Methods section, GFP-positive cells,
isolated by FACS sorting for GFP+ cells, were expanded
and examined by western blot for the cyclin D1 protein
abundance. PC3- (Figure 1A) and 22Rv1- (Figure 2A)
shRNA-cyclin D1 infected cells showed a significant
reduction in cyclin D1 protein expression (Figures 1A
PC3 and 2A 22Rv1). We conducted experiments that
compared tumorigenicity of the shRNA-cyclin D1versus shRNA-control-transduced cells. Delay in cell
growth, cell cycle analysis, soft agar colony formation-,
migration- and invasion-abilities were investigated.
Silencing cyclin D1 leds to a delay in growth of PCa
cells: PC3- and 22Rv1-Cyclin D1-shRNA transduced
cells respectively demonstrated a 5-fold decrease at
10-days and a 2-fold decrease at 12 days in proliferation
compared to control-shRNA transduced cells (Figures 2B
and 3B). FACS analysis shows that silencing cyclin D1
increased the proportion of PC3 (Figure 1C) and 22Rv1
(Figure 2C) cells in G1 phase and up-regulated the p21Waf1
and p27Kip2 cell cycle inhibitor protein expression levels.
Figure 1D (PC3) and 2D (22Rv1) show that silencing
cyclin D1 reduced by 80% (PC3) and 82.5% (22Rv1) the
ability to form colony in soft agar and by 69% (PC3) and
48% (22Rv1) the colony medium size. Figure 1E (PC3)
and 2E (22Rv1) show that cyclin D1 silencing reduced
by 83% (PC3) and 77% (22Rv1) invasion and by 68%
(PC3) and 71% (22Rv1) migration abilities. Given the
observed effects on invasion and migration, the matrix
5384
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metallopeptidase 2 and 9 (MMP-2 and -9) activities were
assessed by ELISA assay. Figures 1F and 2F show that
cyclin D1 depletion reduced the MMP-2 activity by 81%
(PC3) and 82% (22Rv1), the MMP-9 activity by 65%
(PC3) and 62% (22Rv1).

and cyclin D1-shRNA transduced cells were treated with
several doses (0–8 Gy) of radiation. MTT assay (Figure 3A),
performed after 24 hrs post irradiation, shows that silencing
cyclin D1 significantly reduced the PC3 and 22Rv1
cells survival. Colony formation assay was performed
to determine cell reproductive death after treatment
with ionizing radiation. Concordant with the delay in
growth intrinsic to cyclin D1-shRNA transduced cells,
colonies from control-shRNA transduced cells could be
counted after 14 days while those from cyclin D1-shRNA
transduced cells could not be evaluated until 45 days post
irradiation. As shown in Figure 3B, a significant reduction

Cyclin D1 governs the radioresistant phenotype
of PC3 and 22Rv1 cell lines in vitro and in vivo
We investigated the effect of silencing cyclin D1
combined with radiotherapy of human PCa cell lines
in vitro and in vivo. For the in vitro experiments, control-

Figure 1: Stable and Specific Silencing of cyclin D1 inhibits PC3 onco-phenotype. (A) Parental PC3 (PRT), GFP-positive

PC3 cells, stably infected with shRNA-cyclin D1 (CD1) vs. shRNA-control (CTR) sequence (CTR), were selected by FACS sorting and
examined for cyclin D1 protein expression by immunoblotting. (B) Cell growth assay, (C) cell cycle distribution by FACS and p21waf1,
p27KIP2 by immunoblotting, (D) soft agar assay and relative colony size, (E) invasion- and migration-assay and (F) the activation status of
MMP-2 and MMP-9 by ELISA assay were performed. The data presented in Figure 1B, 1C, 1D, 1E and 1F represent the mean ± SD of 3
independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01. For immunoblotting, α-tubulin expression
shows equal loading. Similar results were obtained in n = 3 experiments.
www.impactjournals.com/oncotarget
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in number of cell colonies were observed in cyclin D1shRNA + RT groups compared to control-shRNA group at
all tested doses of radiation in both cell lines. For in vivo
experiments, RT treatment (5 fractions of 2 Gy delivered
over 5 consecutive days for a total dose of 10 Gy) was

started when tumor volume reached 0.5–1.0 mm3 (T0).
Tumor volumes were measured every 4 days for a period
of 24 days (Figure 4A) while tumor weight was measured
at the end of the experiment (Figure 4B). PC3- and 22Rv1cyclin D1-shRNA xenografted mice grew significantly less

Figure 2: Stable and Specific Silencing of cyclin D1 inhibits 22Rv1 onco-phenotype. (A) Parental 22Rv1 (PRT), GFP-positive
22Rv1 cells, stably infected with shRNA-cyclin D1 (CD1) vs. shRNA-control (CTR) sequence (CTR), were selected by FACS sorting and
examined for cyclin D1 protein expression by immunoblotting. (B) Cell growth assay, (C) cell cycle distribution by FACS and p21waf1,
p27KIP2 by immunoblotting, (D) soft agar assay and relative colony size, (E) invasion- and migration-assay and (F) the activation status of
MMP-2 and MMP-9 by ELISA assay were performed. The data presented in Figure 1B, 1C, 1D, 1E and 1F represent the mean ± SD of 3
independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01. For immunoblotting, α-tubulin expression
shows equal loading. Similar results were obtained in n = 3 experiments.
www.impactjournals.com/oncotarget
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with respect to control groups and RT treatment decreased
growth further (Figure 4A). These effects were confirmed
by measuring tumor weight (Figure 4B). The number of
mice with tumor progression significantly differed across
the groups and this was confirmed by the mean values
of TTP (Figure 4C). In the mice xenografted with tumor
cells expressing cyclin D1-shRNA, tumor progressions
occurred within 12 and 14 days after the T0 in PC3 and
22Rv1 tumor cells, respectively (Figure 4C). The mean
TTP of these xenografts was of 11.6 days (95% CI 11.3

to 11.9) in PC3 and 13.4. days (95% CI 13.1 to 13.7) in
22Rv1, respectively. Although an effect of RT, in terms of
tumor weight and tumor volume, was observed in 22Rv1
expressing cyclin D1, a negligible improvement in the TTP
was documented in this xenograft model [13.0. days (95%
CI 12.9 to 13.8)] with respect to controls. In contrast PC3
cells expressing cyclin D1 [15.2. days (95% CI 14.7 to
15.7)] demonstrated, an improvement of the RT response
compared to controls. Interestingly, when cyclin D1 was
silenced the TTP was significantly prolonged (p < 0.05)

Figure 3: Silencing cyclin D1 radiosensitizes PC3 and 22Rv1 cell lines in vitro. shRNA-cyclin D1- (CD1) and shRNA-control-

transduced (CTR) PC3 and 22Rv1 cells were irradiated with various doses (0–8 Gy): (A) MTT and (B) (Upper Panel) colony formation
assays were performed. The data presented in Figure 3A and 3B Upper Panel represent the mean ± SD of 3 independent experiments.
Statistical analysis was performed using the Student’s t-test, P < 0.01. Figure 3B Lower Panel shows the effects of 4 Gy irradiation on
shRNA-cyclin D1- and shRNA-control-transduced PC3 and 22Rv1 cells.
www.impactjournals.com/oncotarget
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with respect to controls and RT resulted in no tumor
progression in both xenograft models (Figure 4C). Masson
trichromic staining was performed to evaluate collagen
deposition and changes in the prostatic parenchymal
architecture (Figure 5, Masson Trichromic). Tumor
masses from control-shRNA transduced cells showed the
presence of nodules surrounded by bundles of connective
tissue together with a massive neovascularization close
to the nodules and throughout the entire parenchyma; RT
treatment did not induce any substantial modification.

Silencing cyclin D1 induced a marked changes in the
morphological pattern with an almost normal parenchymal
architecture, a normal collagen distribution; these effects
were enhanced by RT treatment. Collagen density was
also evaluated by colorimetric assay (Figure 5, % Control
Collagen Density). Silencing cyclin D1 per se decreased
collagen density by 48.2% (PC3) and 59.1% (22Rv1):
these effects were potentiated by RT treatment resulting in
a further decrease of the collagen density by 78.3% (PC3)
and 85.3% (22Rv1). RT did not modify collagen density

Figure 4: Silencing cyclin D1 radiosensitizersPC3 and 22Rv1 cell lines in vivo. Mice xenografted with shRNA-cyclin D1-

(CD1) and shRNA-control-transduced (CTR) PC3 (Left Panel) or 22Rv1 (Right Panel) cells subjected to radiation treatment (5 fractions
of 2 Gy were delivered over 5 consecutive days for a total dose of 10 Gy) starting when the tumor volume reached 0.5–1.0 mm3 (T0).
(A) Tumor volume, (B) tumor weights and (C) number of mice with tumor progression.
www.impactjournals.com/oncotarget
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Silencing cyclin D1 radiosensitizes PCa cells by
impairing the NHEJ-DNA-PKcs and
HR-ATM-RAD51 pathways responsible
for the DNA double-strand break repair

of control-shRNA transduced cells. Vascular response to
silencing cyclin D1 was analyzed by α-SMA staining and
protein expression quantification (Figure 5, α-SMA). There
was significant difference in α-SMA protein expression.
Compared to control-shRNA-transduced group, in
cyclin D1-shRNA transduced group the α-SMA protein
expression was reduced by 61.5% (PC3) and 47.2%
(22Rv1). These effects were enhanced by RT treatment
resulting in a further α-SMA protein expression reduction
by 94.2% (PC3) and 81.3% (22Rv1). Figure 5A and 5B
(cyclin D1) depicts the immunohistochemical analysis and
protein expression quantification for cyclin D1.

We assessed whether silencing cyclin D1 may
sensitize PCa cells to ionizing radiation by inducing
apoptosis and/or promoting the DNA damage and
impairing the molecular mechanisms of DSBs repair. To
this purpose, control- and cyclin D1-shRNA transduced
cells were irradiated with a single dose of 4 Gy and cell
lysates were processed 6 hours after RT. The analysis

Figure 5: Immunohistochemistry, α-SMA and cyclin D1 staining in sections from mice xenografted with PC3 and 22Rv1
cell lines and subjected to radiotherapy. Mice xenografted with shRNA-cyclin D1- (CD1) and shRNA-control-transduced (CTR)

PC3 (Upper Panel) or 22Rv1 (Lower Panel) cells subjected to radiation treatment (5 fractions of 2 Gy were delivered over 5 consecutive
days for a total dose of 10 Gy) starting when the tumor volume reached 0.5–1.0 mm3. Masson’s thrichromic staining, α-SMA and cyclin D1
staining. Original Magnification 10X. Insert: original magnification 40X. (A and B Right Panel) Protein quantification. The data presented
represent the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01.
www.impactjournals.com/oncotarget
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of apoptotic markers show that 4 Gy RT treatment did
not induce significant apoptosis of cyclin D1- versus
control-shRNA transduced cells (Data not shown).
We next tested the abundance of γ-H2AX levels, a
biomarker for DNA double-strand breaks, as well as the
activation status and/or abundance of ATM, DNA-PKcs,
RAD51 and RAD86 that govern the DNA-DSBs repair
machinery. ELISA (Figure 6A) and western blot (Figure
6B, γ-H2AX) showed that in the presence of silencing
cyclin D1, RT significantly increased the DNA damage

as suggested by the upregulation of γ-H2AX protein
expression levels. Cyclin D1 depletion counteracted
DNA-PKcsThr2609 phosphorylation/activation and the
accumulation of RAD51 and Ku86 proteins induced
by RT. No effects on ATMSer1981 phosphorylation status
was observed (Figure 6B). The ability of cyclin D1 to
directly interact with the proteins of DNA-DSBs repair
machinery was investigated. PC3 and 22Rv1 cells
were irradiated with a single dose of 4 Gy and, after 6
hours, cell lysates were immunoprecipitated for cyclin

Data not shown. Cyclin D1 silencing did not radiosensitize by inducing apoptosis. control- (CTR) and cyclin D1-shRNA (CD1)

transduced PC3 and 22Rv1 cells were subjected to 4 Gy of irradiation. (A) TUNEL assay and the evaluation of caspase-3, -8 and -9
activation by ELISA (B) and western blott (C) assays were performed after 6 hours from irradiation. The data presented in A and B represent
the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01.
www.impactjournals.com/oncotarget
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D1: PKcsThr2609, -ATMSer1981 and RAD51 association
was tested by immublotting. Cyclin D1 bound DNAPKcsThr2609, -ATMSer1981 and RAD51 and the amount of
activated-DNA/PK,-ATM and RAD51 was significantly
increased by RT treatment (Figure 6C). The relationship
between cyclin D1 and DNA-DSBs repair machinery was
also tested in in vivo experiment on mice xenografted with
control- or cyclin D1-shRNA transduced PC3 or 22Rv1
cells, treated or not with RT as already described and
sacrificed 24 hours after the last RT dose (Figure 7). Also
in in vivo, silencing cyclin D1 favored the DNA-DSBs

damage, impairing the DNA-damaged repair. In presence
of cyclin D1 silencing, RT increased γ-H2AX expression
by 281% (PC3) and 246% (22Rv1) (Figure 7 γ-H2AX)
while poor DNA-PKcs activation (DNA-PKcsThr2609),
Ku86 and RAD51 protein expression (Figure 7) were
identified. Lastly we investigated if DNA-PKcs- and/
or ATM-RAD51-pathways were downstream targets of
cyclin D1-mediated radioresistance. To this end, PC3 and
22Rv1 cells subjected to DNA-PKcs or RAD51 protein
silencing with specific siRNA, were irradiated with a
single dose of 4 Gy: γ-H2AX levels were tested by ELISA

Figure 6: cyclin D1 depletion do not radiosentize via inducing apopotosis but rather by impairing the molecular
machinery responsible of the DNA double-strand break repair. shRNA-cyclin D1- (CD1) and shRNA-control-transduced (CTR)

PC3 or 22Rv1 cells irradiated with a single dose of 4 Gy. (A) 6 hours post RT, H2AX activation status was investigated using and ELISA
assay for γ-H2AX; the data represent the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s
t-test, P < 0.01. (B) Cell lysate were processed for the indicated proteins by immunoblotting; α-tubulin demonstrates equal loading. Similar
results were obtained in n = 3 experiments. (C) Cyclin D1-DNA-PKCs, -ATM, -RAD51 heterodimers in PC3 (Upper Panel) or 22Rv1
(Lower Panel) cells untreated (−) or treated (+) with RT (4 Gy). 6 hours post RT, cyclin D1 was immunoprecipitated (IP) with an anti-cyclin
D1 polyclonal antibody from extracts containing equal amounts of total proteins and subsequently analyzed by immunoblotting with a
cyclin D1, DNA-PKCsThr2809, ATMSer1981 or RAD51 monoclonal antibodies. Similar results were obtained in n = 2 experiments.
www.impactjournals.com/oncotarget
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Figure 7: Cyclin D1staining in sections from mice xenografted with PC3 and 22Rv1 cell lines and subjected to
radiotherapy. Mice xenografted with shRNA-cyclin D1- (CD1) and shRNA-control-transduced (CTR) PC3 (Upper Panel) or 22Rv1

(Lower Panel) cells subjected to radiation treatment (5 fractions of 2 Gy were delivered over 5 consecutive days for a total dose of 10 Gy)
starting when the tumor volume reached 0.5–1.0 mm3: γ-H2AX, Pospho-DNA-PKCs, Ku86 and RAD51 staining and protein quantification.
The data represent the mean ± SD of 3 independent experiments. Statistical analysis was performed using the Student’s t-test, P < 0.01.
www.impactjournals.com/oncotarget
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DISCUSSION

at different time post RT treatment. siRNA transfection
resulted in a downregulation of DNA-PKcs or RAD51
expression with respect to the siRNA-control-transfected
cells (Figure 8A). ELISA (Figure 8B) show that DNAPKcs or RAD51 silencing significantly favored the DNA
damage induced by RT. Contrary to siRNA-controltransfected cells, in which the γ-H2AX upregulation was
transient and disappeared within 12 hours, DNA-PKcs
or RAD51 silencing favored a greater and more lasting
effect on DNA damage, suggesting DNA-PKcs- and ATM/
RAD51-pathway are downstream targets of cyclin D1
induced PCa cell radioresistance.

Radiation therapy (RT) is considered the first line
treatment for prostate cancer (PCa). Despite technical
improvements, many patients relapse locally and/or
with systemic disease, indicating the presence of a radio
resistant cancer cell population [1–2]. Furthermore,
several evidence show that PCa cells with an androgenindependent phenotype have higher biochemical failure
rates after RT suggesting that androgen-independency
may be associated with radiation resistance in PCa [3].
Cancer cells are frequently characterize by an elevated

Figure 8: Effects of RAD51 or DNA-PKcs siRNA on DNA damage. (A) Reduced RAD51 or DNA-PKcs expression by

RAD51 or DNA/PKcs siRNA. Western blot analysis performed using lysates isolated from PC3 (Left Panel) or 22Rv1 (Right Panel) cells
expressing RAD51, DNA-PKcs or Control siRNA and subjected to 4 Gy of RT. Cell lysates were processed for the indicated proteins by
immunoblotting; α-tubulin expression shows equal loading. (B) H2AX activation status was investigated by using an ELISA assay for
γ-H2AX at different time from RT treatment; the data represent the mean ± SD of 3 independent experiments. Statistical analysis was
performed using the Student’s t-test, P < 0.01. Similar results were obtained in n = 3 experiments.
www.impactjournals.com/oncotarget
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DNA repair capacity that leads to radiation resistance
and targeting the DNA repair machinery could enhance
the efficacy of RT [10–11]. In previous studies Ccnd1
gene deletion was associated with reduced proliferation
of prostate epithelial cells and induction of a cyclin D1
mediated gene signature that predicted poor outcome
and recurrence free survival in prostate cancer patients
[16]. Herein, we investigated if cyclin D1 contributes to
androgen-independent PCa cells radioresistance. The role
of cyclin D1 in androgen-independent PCa cells response
to RT was previously unknown. By using androgenindependent, androgen-receptor negative PC3 [23–24]
and androgen-receptor positive 22Rv1 [25] PCa cell lines
stable infected with shRNA for cyclin D1, we show that
cyclin D1 is a key regulator in controlling the DNA double
strand break (DSB) repair mechanisms mediated by the
non homologous end joining (NHEJ) pathway and that the
silencing cyclin D1 radiosensitizes PCa cells.
D-type cyclins (D1, D2, and D3) are G1-specific
cyclins that promote restriction point progression during
G1 phase [12]. Amplification of individual cyclin D

genes and overexpression of their encoded proteins were
documented in a large proportion of human cancers
[12–16]. Cyclin D1 protein expression is induced by
growth factors in human PCa cell lines and is increased
in a subset of PCa samples, promoting PCa cell growth
[15, 30]. Previous studies show that silencing cyclin D1
reduced growth in vitro and in vivo [14, 16] while its
overexpression increased cell growth and tumorigenicity
of androgen-dependent, androgen receptor-expressing
LnCAP cells [31]. In the current studies, silencing cyclin
D1 affected the tumorigenic potential of androgenindependent PC3 and 22Rv1PCa cell lines in vitro and
in vivo independently of the expression of androgen
receptor. Silencing cyclin D1 in PCa cells showed a
significant growth delay both in vitro and in vivo, with
many cells arrested in the G1 phase of the cell cycle.
Furthermore, cells cannot expand for more than 6
passages. Cancer cell tumorigenicity is characterized by
the strong ability of cancer cells to invade and migrate
[32]. Cyclin D1 plays an important role in cell migration
[33] promoting the migratory and invasive capacity of

Figure 9: Cyclin D1 promotes NHJE and HR pathways responsible of DNA-DSBs repair. Schematic representation depicting
the collaboration of cyclin D1 with the molecular pathways responsible for the DNA-DSBs repair. In dashed line, the molecular mechanism
by which it is necessary to verify whether the action of cyclin D1 is direct or mediated by other factors.
www.impactjournals.com/oncotarget
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macrophages [34], fibroblasts [35], breast epithelial
cells [36] and human glioblastoma cells [37–38]. The
mechanism, rather complex, is via RhoA and binding to
the cytoplasmic proteins Filamin A [39], Pacsin 2 [40] and
the regulation of microRNAs such as microRNA-17/20
[41]. Furthermore, cyclin D1 regulates metalloproteinase
(MMPs) [42–43], traditionallyassociated with matrix
remodeling, cancer invasion and with angiogenesis. Here,
in characterizing the tumorigenic phenotype of cyclin D1
silenced PCa cell lines, we showed that migration and
invasion abilities as well as MMP2 and MMP9 activities
were drastically reduced in the absence of cyclin D1.
Cancer progression, invasion, and metastasis are processes
strictly correlated with angiogenesis that plays a key role in
PCa disease progression [44]. Herein silencing cyclin D1
induced in vivo changes in tumor vascularity and structural
organization, impairing the amplitude and architecture of
the vascular bed. These effects could are in accordance
with studies demonstrating cyclin D1depletion inhibits
VEGF -stimulated growth of vascular endothelial cells
causing several abnormalities to the normal organization
of the vascular bed [45–46]. Our evidences indicated that
cyclin D1 is essential for the maintenance of PCa cells
tumorigenic abilities and that cyclin D1 depletion alone
can reverts the oncogenic phenotype.
RT works through damaging the DNA of exposed
tumor tissue leading to cell death: DNA double-strand
breaks (DSBs), the most deleterious lesions, are repaired
by two main pathways namely non-homologous end
joining (NHEJ) and homologous recombination (HR).
Activation of DSBs repair genes is one of the reasons
for chemo- and radioresistance, therefore, targeting
DSBs repair is an attractive strategy to eliminate cancer
[6–9]. The relationship between cyclin D1 and DSBs
repair machinery is largely unknown and the fact that
cyclin D1 has the hallmarks of a cellular proto-oncogene
suggests its possible key role in promoting DNA repair
and consequently promote radioresistance of PCa cells.
Previous studies reported a correlation between cyclin D1
overexpression, perturbation of the DNA repair machinery
and acquisition of a radioresistant phenotype in cancer cells
[17–22]. No evidences has yet collected on the relationship
between cyclin D1 and radiosensitivity of androgenindependent PCa cells radioresistance. Herein, silencing
cyclin D1 radiosensitizedandrogen-independent PCa cell
lines both in vitro, reducing cells clonogenic survival, and
in vivo impairing xenograft growth of the PCa cells after
RT treatment. Cancer cells escape from RT by repairing
the DNA lesions trough the activation of highly conserved
enzymatic pathways: only the accumulation off rank
unrepaired breaks may generate chromosomal aberrations
that, after a variable number of cell cycles, induce cell
death. This mode of cell death is considered the major
mechanism by which solid tumors respond to clinical
radiotherapy. Apoptosis is an alternative mode of cell
death after RT, but appears to be preferentially expressed
www.impactjournals.com/oncotarget

in embryonal and haematopoietic cells, with significantly
lower levels of induction in epithelial cell types as well as
in solid human cancers with an epithelial origin [47]. Our
data shows that the radiosensitization induced by silencing
cyclin D1 does not depend on apoptosis but rather by
an increased accumulation of DNA-DSBs damage; RT
treatment did not modify the percentage of apoptotic
cells regardless of the expression of CCDN1, while it
drastically increased DNA-DSBs damage, as suggested by
the accumulation of activated H2AX protein [48]. Our data
indicate that in PCa, such as in other cancers of epithelial
origin, RT induces cell death by promoting DNA-DSBs
phenomena; in this scenario cyclin D1 seems to be the
guardian against RT-induced DNA damages. HR, through
the ATM-RAD51-and NHEJ, via the DNA-PKcs-pathway,
are the main highly conserved enzymatic pathways
involved in repair of RT-induced DNA-DSBs [6–10].
We finally investigated the molecular partners of cyclin
D1 responsible of cyclin D1-mediated radioresistance in
PCa. A proteomic screen for cyclin D1 protein partners,
performed in several types of human tumors, shows that
cyclin D1 interacts with proteins implicated in DNA repair
machinery such as RAD51 [17–22]. Herein, in vitro and
in vivo, we show that cyclin D1 silencing abrogated the
DNA-PKcs phosphorylation/activation (NHEJ pathway)
and RAD51 accumulation (HR pathway) induced by RT.
Although no modifications of ATM phosphorylation/
activation status were showed, we found that cyclin
D1physically interacts with posphorylated-activated-ATM
as well as with activated-DNA-PKcs and RAD51: their
associatedis increased in an RT dependent manner. Thus,
cyclin D1 seems to play a dual role in controlling DNADSBs repair pathways; firstly by regulating NHEJ and HR
pathways by sustaining the activation of DNA-PKcs, ATM
and the expression basal levels of RAD51 and secondly by
directly interacting with the DNA-DSBs repair machinery.
The key role cyclin D1 in regulating androgen independent
PCa cells radioresistance was also demonstrated by
the observation that silencing of DNA-PKcs or RAD51
drastically increases the radiosensitivity of PCa cells.
Thus, our evidence strongly suggests that cyclin D1
regulates the activity of downstream DDR machinery
and promotes radioresistance of androgen independent
PCa cells. The schematic shown in Figure 9 outlines the
mechanism identified in our findings. Many issues should
be further investigated such as the mechanisms by which
cyclin D1 regulates the RT-induced ATM and DNA-PKCsphosphorilation/activation, the mechanism by which
cyclin D1 influences the RAD51 RT-induced DDR and
the significance of the physical interaction between cyclin
D1 and other members of DNA-DSBs repair machinery.
Furthermore, cancer stem cell radioresistance has been
described in several cancer types including prostate cancer
[49–50] and it will be of interest to test whether silencing
cyclin D1 in PCa cells that express stem-like properties
improves radiosensitivity.
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In the present study, we demonstrated that cyclin
D1 governs the tumor phenotype and participates in
determining radioresistance of PCa cells independently by
androgen receptor expression. Our studies suggest silencing
cyclin D1 may improve the therapeutic effects of RT.

after 24 hours with 100 nM siRNA, which we ascertained
was sufficient to detect maximum fluorescence using
fluorescein-conjugated control siRNA.

Cell growth, soft agar colony formation, invasion
and migration assays

MATERIALS AND METHODS

Cells (20x104/well) were plated in 24-well culture
plates. The cell number was assayed by crystal violet
staining at 2-day intervals up to 20 days. Medium was
changed every 4 days. Control cells were analyzed under
the same conditions until they reached confluence. In
order to evaluate the ability of individual cell lines to grow
in an anchorage-independent manner, cells were plated in
soft agar. The bottom of each well contained 2 ml of 0.5%
agarose and RPMI 2X (Sigma Aldrich Corporation, St
Louis, MO, USA). This compact agar was covered with
2 ml of 0.2% agar and RPMI 2X with 5 × 103 cells. The
medium was changed every 3 days. After 21 days, the
wells were stained with 0.003% crystal violet, and five
areas were randomly selected from each well in order
to count the approximate number of colonies. The cellmigration and invasion assays were performed using the
CytoSelect™ ECM Cell Migration and Invasion Assay
(8 µm, Colorimetric Format) (CELL BIOLABS, INC.) in
accordance with manufactures instructions.

Cell culture and FACS analysis
The human prostate carcinoma cell lines 22Rv1,
and PC3 were obtained from the American Type Culture
Collection (Rockville, MD) and were grown in RPMI 1640
(Life Technologies, Inc., Grand Island, NY) supplemented
with 10% FBS. For FACS analysis cells were harvested
by trypsin-EDTA and washed; pellets were suspended in
0.3 ml 50% FCS in PBS, followed by addition of 0.9 ml
70% ethanol and left O/N in the dark at 4°C prior to FACS
analysis (Coulter Epics XL Flow Cytometer, Beckman
Coulter CA, USA).

Viral production and infection and siRNA
interference
Design of nucleotide sequence for cyclin D1short
hairpin RNA (GCCACAGATGTGAAGTTCA) was
performed with the BLOCK-iT™ RNAi Designer from
Invitrogen. shRNA was designed that incorporated these
sequences within a short hairpin structure, using the stem
loop sequence 5′-TCAAGAGA-3′, which were then
cloned between MluI and ClaI sites downstream of an H1
promoter in the plasmid pLVTHM. Plasmid pLVTHM,
derived from pSUPERn that contains a GFP expression
cassette upstream of the H1 promoter, was obtained
from Addgene. The construct was stably transduced into
PC3 and 22Rv1 cells using a lentiviral based expression
system [26]. 293T cells were transfected using calcium
phosphate transfection together with the packaging
vectors psPAX2 (virus packaging plasmid) and pMD2G
(Addegene) (envelope plasmid; 4:3:2 ratio) by calcium–
phosphate transfection. Culture medium containing virus
was collected 48 hours after transfection and filtrated
through a 0.4 μm filter to remove cell debris and cells:
viral titers were determined by measuring the percent of
green fluorescent protein (GFP)–positive cells. Stable cell
lines expressing shRNA were achieved by infection at
50 multiplicity of infection (MOI). The collected viruses
were added to the target cells in the presence of polybrene
(2 μg/mL) and incubated for 24 hours. Four days after the
first infection, transduced cells were isolated by FACS
sorting for GFP + cells to > 99% purity. RNA interference
experiments were performed with siRNA for DNAPKcs, ATM and RAD51 (Sancta Cruz Biotechnology)
using Lipofectamine 2000 reagent (Invitrogen, Italy),
according to the manufacturer’s instructions. Briefly,
cells were plated at 40–50% confluence and transfected
www.impactjournals.com/oncotarget

Immunoblotting
Immunoblotting was performed as previously
described [27] using the following antibodies: anticyclin D1(DCS-6), anti-ATM (H-248), anti-DNA-PKcs
(E-6), anti-H2AX (M-20), anti-p-H2AX (3C10), antiRAD51 (3C10), anti-Ku86 (B-1), anti-p21waf1 (B-2),
anti-p27Kip1 (A-10) and α-tubulin (B-7) all from Santa
Cruz Biotechnology. Anti-pospho-Ser1981-ATM (10H11.
E12), anti-pospho-Thr2609-DNA-PKcs (10B1) were
from abcam®. Peroxidase-conjugate anti-mouse or antirabbit IgG (Amersham-Pharmacia Biotech, UK or Santa
Cruz) were used for enhanced chemiluminescence (ECL)
detection.

Immunoprecipitation
Cells were harvested in phosphate buffered saline,
sedimented and lysed in 10 mM Tris pH 7, 50 mMNaCl,
1% NP40, 1 mM ZnCl2, in addition to protease and
phosphatase inhibitors. Protein extracts were clarified
by centrifugation. Supernatant, normalized as equal
amounts of proteins, were incubated with antibody anticyclin D1(H-295RabbitPolyclonal) at 4°C for 3 hrs. 30
μl of protein-G Plus (Santa Cruz Biotechnology) were
added to collect immunocomplexes. Protein G-bound
immunocomplexes were washed 6 times with extraction
buffer and processed for SDS-PAGE. Immunoblotting
was performed with anti-RAD51 (3C10) from Santa Cruz
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Biotechnology or with anti-pospho-Ser1981-ATM (10H11.
E12), anti-pospho-Thr2609-DNA-PKcs (10B1) from
abcam®: all the antibodies used for the immunoblotting
were mouse monoclonal.

an Elekta6-MV photon linear accelerator. Five fractions
of 2 Gy were delivered over 5 consecutive days for a total
dose of 10 Gy with a dose rate of 1.5 Gy/min. Prior to
irradiation, mice were anesthetized and were shielded from
off-target radiation by a multi-leaf secondary collimator.
Before tumor inoculation mice were randomly assigned to
2 experimental groups, with or without radiation treatment.
Each group was composed of 10 mice. Experiments were
stopped 20 days after the last RT fraction and mice were
sacrificed by carbon dioxide inhalation. Tumours were
directly frozen in liquid nitrogen for protein analysis and
biochemical evaluation. All the procedures involving
animals and their care were conducted in accordance with
the institutional guidelines.

In vitro irradiation and colony formation assay
Radiation was delivered at room temperature
using an x-6 MV photon linear accelerator, as previously
described [28]. The total single dose of 4 Gy was delivered
with a dose rate of 2 Gy/min using a source-to-surface
distance (SSD) of 100 cm. A plate of Perspex thick 1.2
cm was positioned below the cell culture flasks in order to
compensate for the build-up effect. Tumor cells were then
irradiated placing the gantry angle at 180°. Non-irradiated
controls were handled identically to the irradiated
cells with the exception of the radiation exposure. For
clonogenic survival assays, exponentially growing cells in
25-cm2 flasks were harvested by exposure to trypsin and
counted. They were diluted serially to appropriate densities
and plated in triplicate in 6 multi-well plates with 2 mL of
complete medium/each well. After incubation for 24 hours,
the cells were exposed at room temperature to radiation
treatment as already described. The cells were then washed
with PBS, cultured in growth medium for 14 days, fixed
with methanol:acetic acid (10:1, v/v), and stained with
crystal violet. Colonies containing > 50 cells were counted.

Evaluation of treatment response in vivo
The effects on tumour growth of different treatments
were evaluated as follows: (1) measurement of tumour
volume during and at the end of experiments. Tumor
volume was assessed by measurement every 4 days with a
Vernier calliper (length × width). The volume of the tumor
was expressed in mm3 according to the formula 4/3π r3;
(2) measurement of tumor weight at the end of experiment;
(3) Time to progression (TTP), defining tumor progression
(TP) an increase of greater than 100% of tumor volume
with respect to baseline.

Cell viability, apoptosis, caspases- and γ-H2AX
activation assays

Histological and immunohistochemical analysis
Serial 3 µm sections were stained with Hematoxylin
and Eosin (H&E) and Masson’s Trichrome in order to
evaluate morphological aspects. For immunohistochemical
(IHC) analysis, sections were incubated for 40 minutes in
methanol and 3% hydrogen peroxidase solution and then
rinsed in PBS. Samples were incubated 10 minutes in
buffered citrate 0.01 M, pH 6, twice and rinsed in PBS.
Sections were then treated with BSA (5%) for 10 minutes
and finally incubated overnight with specific antibodies
against cyclin D1 (H-295), RAD51 (H-92), Ku86
(H-300), α-Actin (1A4) and p-ATM (10H11.E12) all from
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA,
γH2AX (IB 100–2280) from NOVUS biologicals, used at
dilutions of 1:100. Samples were then rinsed with PBS
for 5 minutes and incubated with a labeled streptavidinbiotin-peroxidase conjugate kit (Dako LSAB plus, cod.
K0675, DakoCytomation, Milan, Italy). After rinsing in
PBS for 10 minutes the sections were incubated with 3,
3-diaminobenzidine-tetrahydrochloride (DAB, Sigma
Aldrich) for 1–3 minutes. The specificity of immune
reactions was revealed by the absence of the primary
antibodies. Lastly, the samples were counterstained
with Mayer’s Hematoxylin and observed under a
photomicroscope Olympus BX51 Light Microscope
(Olympus, Optical Co. Ltd, Tokyo, Japan). Observations

A Cell Proliferation Kit I (MTT) (Sigma-Aldrich)
was used to quantitatively measure cellular viability.
Tunnel assay (Promega) was used to quantitatively
measure the cellular apoptosis. Caspase-Glo®3, 8 and
9 assays from Promega were used to measures caspase
activity. All assays were performed accordingly to the
manufacturer’s instructions.

Establishment of tumor xenografts and in vivo
radiation treatment
PCa cells were grown to 80% confluence and
harvested. Cells were re-suspended in serum free RPMI1640 medium with penicillin and streptomycin, mixed
1:1 with Growth Factor Reduced (GFR) BD Matrigel
Basement Membrane Matrix (BD Biosciences, Palo
Alto, California). Using a cold syringe and 27-gauge
needle, 3.5 × 106 PC3 and 5 × 10622Rv1 cells were
injected subcutaneously into each lateral flank of male
athymic nu/nu mice 6 weeks of age. Mice were kept under
sterile conditions, receiving sterile nutrition and water.
When palpable tumors (0, 5–1, 0 cm3) were established
animals were subjected to radiation treatment. Mice were
irradiated by two field (AP/PA) at room temperature using

www.impactjournals.com/oncotarget
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were processed with an image analysis system (IAS, Delta
system, Rome, Italy) and were independently performed
by two pathologists (AV, RS) in a blinded fashion.

variance for independent groups). Dichotomous variables
were summarized by absolute and/or relative frequencies.
For Dichotomous variables, statistical comparisons
between control and treated groups were established
by carrying out the exact Fisher’s test. For multiple
comparisons the level of significance was corrected by
multiplying the P value by the number of comparisons
performed (n) according to Bonferroni correction. TTP
was analyzed by Kaplan-Meier curves and Gehan’s
generalized Wilcoxon test. When more than two survival
curves were compared the Logrank test for trend was used.
This tests the probability that there is a trend in survival
scores across the groups. All tests were two-sided and were
determined by Monte Carlo significance. P values < 0.05
were considered statistically significant.
For TTP, fractional TTP (FTTP) for each treatment
group was calculated as the ratio between the median
TTP of untreated and treated tumors. This was done
for treatment a, for treatment b and for treatment
a + b. The expected FTV or FTTP for the << a + b >>
combination was defined as FTVa-observed X FTVbobserved or as FTTPa-observed X FTTP-observed.
The ratio FTV a + b-expected/FTV a + b-observed
or FTTP a + b-expected/FTTP a + b-observed was
the combination Index (CI). If CI > 1, there are
supra-additive effects and if CI < 1 infra-additive
ones. Strictly additive effects are observed if CI = 1.
All statistical analyses were performed using the SPSS®
statistical analysis software package, version 10.0.

In vivo densitrometric quantification of proteins
Densitometric analysis for α-SMA and cyclin D1
was obtained using “IHC Profile ImageJ” an automated
digital program quantitates the intensity of antibody
staining in tissue sections. The spectral deconvolution
method of DAB/hematoxylinwas deployed, so that the
DAB stained images could be separated and displayed
independent of the hematoxylin image. Then the program
selects where the marker protein is expressed the most,
cytoplasm and/or nucleus. Therefore the deconvoluted
image undergoes a pixel-by-pixel analysis, thus the full
profile along with a scoring decision is provided. The
results are shown in a four tier system which includes high
positive, positive, low positive and negative.

Colorimetric evaluation of collagen content
Samples (5 mm3) of tumor xenograft were removed
and immediately immersed in 10% buffered formalin
for paraffin embedding. Eight 15-mm thick, 100 mm2
large sections were obtained from each liver and used for
colorimetric evaluation. Sections for colorimetric evaluation
were deparaffinized through successive baths in absolute
toluene: ethanol (50:50) and 50% aqueous ethanol and water.
Staining procedures with fast green FCF 0.1 (ChromaGesellshaft, no. IA30, Stuttgart, Germany) and Sirius Red
F3B 0.01% (Atomergic Chemical Corporation, no. 10022;
Plainview, NY, USA) were performed according to GasconBarrè et al. [29]. Colors were eluted in 0.05 MNaOH and
50% aqueous methanol. The eluted colors were examined
in Lambda 4 B PE spectrophotometer. Correlation
between absorbance and protein estimations were assessed
according to Gascon-Barrè et al. [29]. Non-collagenous
protein determination was obtained using the following
formula: Non-collagenous protein (mg) = Absorbance
at 605 nm / 2.08. Collagenous protein determination was
obtained using the latter interference factor in the following
formula: Collagen (μg) = (Absorbance at 540 nm) – (0.26
absorbance at 605 nm) / 38.4 Collagen content ( collagen /
protein ratio) was calculated using the following formula:
Collagen content (μg/mg total protein) = μg collagen /
(μg collagen + mg non-collagenous protein) [29].
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